DEBBRAH

NCT04420598 📎

Regimen

Experimental
Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (single-arm, multi-cohort).
Control
N/A (single-arm).

Population

HER2-positive or HER2-low metastatic breast cancer with leptomeningeal disease or untreated/progressing brain metastases, five cohorts.

Key finding

DEBBRAH extended TUXEDO-1 data by documenting T-DXd activity specifically in leptomeningeal disease and stable/progressing brain metastases across multiple HER2 expression levels. Builds evidence base for ADC use in CNS disease.

Timeline

    Guideline citations

    • NCCN BREAST